key: cord-0850220-jc83jxrh
authors: Seeland, U.; Coluzzi, F.; Simmaco, M.; Mura, C.; Bourne, P. E.; Heiland, M.; Preissner, R.; Preissner, S.
title: Evidence for treatment with estradiol for women with SARS-CoV-2 infection
date: 2020-08-24
journal: nan
DOI: 10.1101/2020.08.21.20179671
sha: 2d4a997428dd7b8c6e04c06642a6e0ca8679e83a
doc_id: 850220
cord_uid: jc83jxrh

BACKGROUND Given that an individual's age and gender are strongly predictive of COVID-19 outcomes, do such factors imply anything about preferable therapeutic options? METHODS An analysis of electronic health records for a large (68,466-case), international COVID-19 cohort, in five-year age strata, revealed age-dependent sex differences. In particular, we surveyed the effects of systemic hormone administration in women. The primary outcome for estradiol therapy was death. Odds Ratios (ORs) and Kaplan-Meier survival curves were analyzed for 37,086 COVID-19 women in two age groups: pre- (15-49 years) and post-menopausal (>50 years). RESULTS The incidence of SARS-CoV-2 infection is higher in women than men (about +15%) and, in contrast, the fatality rate is higher in men (about +50%). Interestingly, the relationships between these quantities are also linked to age. Pre-adolescent girls had the same risk of infection and fatality rate as boys. Adult premenopausal women had a significantly higher risk of infection than men in the same five-year age stratum (about 16,000 vs. 12,000 cases). This ratio changed again in postmenopausal women, with infection susceptibility converging with men. While fatality rates increased continuously with age for both sexes, at 50 years there was a steeper increase for men. Thus far, these types of intricacies have been largely neglected. Because the hormone 17{beta}-estradiol has a positive effect on expression of the human ACE2 protein--which plays an essential role for SARS-CoV-2 cellular entry--propensity score matching was performed for the women's sub-cohort, comparing users versus non-users of estradiol. This retrospective study of hormone therapy in female COVID-19 patients shows that the fatality risk for women >50 yrs receiving estradiol therapy (user group) is reduced by more than 50%; the OR was 0.33, 95 % CI [0.18, 0.62] and the Hazard Ratio was 0.29, 95% CI [0.11,0.76]. For younger, pre-menopausal women (15-49 yrs), the risk of COVID-19 fatality is the same irrespective of estradiol treatment, probably because of higher endogenous estradiol levels. CONCLUSIONS As of this writing, still no effective drug treatment is available for COVID-19; since estradiol shows such a strong improvement regarding fatality in COVID-19, we suggest prospective studies on the potentially more broadly protective roles of this naturally occurring hormone.

propensity score matching was performed for the women´s sub-cohort, comparing users 23 versus non-users of estradiol. This retrospective study of hormone therapy in female COVID- 24 19 patients shows that the fatality risk for women >50 yrs receiving estradiol therapy (user 25 group) is reduced by more than 50%; the OR was 0. 33 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 24, 2020. . https://doi.org/10.1101/2020.08.21.20179671 doi: medRxiv preprint of COVID-19 fatality is the same irrespective of estradiol treatment, probably because of higher 1 endogenous estradiol levels. As of this writing, still no effective drug treatment is available for COVID-19; since estradiol 4 shows such a strong improvement regarding fatality in COVID-19, we suggest prospective 5 studies on the potentially more broadly protective roles of this naturally occurring hormone. Early epidemiological observations indicated that SARS-CoV-2 infects all age groups, but with 12 a higher rate among men (58.1%) than women (41.9%) (Guan et al., 2020) . The fraction of 13 males among critically ill patients testing positive for COVID-19 is higher, and the outcome is 14 far worse than for women (among casualties, 66% are male and 34% are female) (Yang et al., 15 2020). From a medical perspective of sex and gender, considering the epidemiological data in 16 a more differentiated manner-based, for instance, on age, sex and lifestyle/behavior 17 patterns-may enable the identification of sub-populations with increased susceptibility (or 18 resistance) to SARS-CoV-2 infection. 19 As an example of such nuances, consider that spread of the viral infection exhibits a 20 sex-dependence, and also a higher fatality rate amongst older patients, >60 yrs in age (Verity 21 et al., 2020; Zhou et al., 2020). In addition, smoking behavior has been one of the most 22 appreciated gender differences thus far, and it may underlie the far worse outcomes in men 23 than in women (Cai, 2020) ; however, this trend has not been confirmed beyond a handful of 24 countries, and the causal aspects of these trends are likely to be rather complex. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 24, 2020. . https://doi.org/10.1101/2020.08.21.20179671 doi: medRxiv preprint Pathophysiological Context 1 SARS-CoV-2 virions use the angiotensin-converting enzyme 2 (ACE2) as a host-cell receptor 2 (Hoffmann et al., 2020) for viral uptake. Human ACE2 is an essential part of the renin- 3 angiotensin system (RAS), and is encoded on the X chromosome (Crackower et al., 2002) . 4 ACE2 is widely distributed in tissues, including lung alveolar (type II) epithelial cells, the 5 vascular endothelium, heart, kidney, and testis (Gheblawi et al., 2020) . It has extensive 6 vascular and organ-protective functions mediated via angiotensin (Ang 1-7) by the angiotensin 7 II receptor type 2 (AT2) and the Mas receptor (MasR). Seeland et al. have reviewed the sexual 8 dimorphism, by virtue of the X chromosomal gene location of ACE2 and the AT2 receptor, as 9 well as the effects of 17ß-estradiol on different components of the renin-angiotensin-10 aldosterone system (RAAS) (Seeland & Regitz-Zagrosek, 2012) . Estrogens downregulate the 11 angiotensin II receptor type 1 (AT1R) signaling pathway by inhibiting angiotensin-converting 12 enzyme (ACE) activity (which, in turn, diminishes the production of angiotensin II peptide). This 13 classical ACE/AngII/AT1R regulatory axis counter-regulates the ACE2/Ang 1-7/MasR axis.

Based on gender-specific differences in genetics and sex hormone levels, the worse outcomes 16 of SARS-CoV-2 infection in men could be triggered by (i) conditions that are associated with a 17 decrease in ACE2 expression, such as older age (Xie, Chen, Wang, Zhang, & Liu, 2006) or 18 (ii) by the more direct loss/depletion of active ACE2 (e.g., because of binding by SARS-CoV- 19 2). Moreover, the regulation of immune cells and cytokine activity are also linked to sex 20 hormone levels. In terms of disease etiology, this could represent another set of factors that 21 underlies the sex differences in pulmonary and vascular symptoms, severity, and outcomes of 

Objectives of this Study 26 As is known from the literature, endogenous estradiol has beneficial cardiovascular and 27 immune system-stabilizing effects in premenopausal women, as well as within pregnancy 28 . CC-BY 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 24, 2020. . https://doi.org/10.1101/2020.08.21.20179671 doi: medRxiv preprint (Dubey & Jackson, 2001; Straub, 2007) . We hypothesize that exogenous estradiol intake is a 1 protective strategy in pre-and post-menopausal women suffering from SARS-CoV-2 infection. This study assesses the effects of exogenous sex hormone intake from oral contraceptives by 4 premenopausal women, and estradiol hormone therapy by postmenopausal women with 5 SARS-CoV-2 infection or COVID-19 disease on the outcome death. In the present work, we conducted a retrospective analysis of a large international 16 COVID-19 cohort comprising 68,466 cases. Sub-cohorts were disaggregated by age (15+ 17 years) and sex before statistical analyses were performed. The incidence data are presented 18 in age steps of five years, from 5 to 86+ years for both sexes. Because of the expected estradiol 19 hormone status, two subgroups of the female cohort were analyzed: we defined 15-49 years 20 as the younger (pre-menopausal) group and 50+ for the older (post-menopausal) group. The is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 24, 2020. . https://doi.org/10.1101/2020.08.21.20179671 doi: medRxiv preprint slow and expensive. Furthermore, classical trials generally represent artificial situations with 1 well-selected-and thus non-representative-pools of patients (e.g., often young men with few 2 to no co-morbidities). Some of these issues can be alleviated by turning to RWE gleaned from 3 EHR-derived data. Despite all this, one disadvantage of retrospective, implicit recruitments is 4 the missing randomized placebo arm of the statistical study. Thus, generating suitable control 5 cohorts is one of the most important aspects of an RWE-based study. One significant 6 advantage of RWE is the large number of patients who can be recruited-this, in turn, yields 7 relatively tighter confidence intervals and allows for cohort balancing or patient matching. In The TriNetX platform ensures data quality control by processes and procedures triggered in 13 response to questions about the data provided. TriNetX provides details on the data 14 provenance and/or offers the necessary access to audit the processes. TriNetX also makes 15 the data available for a third-party audit. 16 

The consolidated standard of reporting trial (CONSORT) flow diagram, shown in Figure 1 , 19 illustrates the data extraction process from the TriNetX Real-World database. The full cohort is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 24, 2020. . https://doi.org/10.1101/2020.08.21.20179671 doi: medRxiv preprint Regarding gender medicine aspects and analyzing the data in terms of 5-year age strata, the 19 incidence rates of women and men with known SARS-CoV-2 infection can be seen to differ by is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 24, 2020. . https://doi.org/10.1101/2020.08.21.20179671 doi: medRxiv preprint 8 in this pre-menopausal age group is about +15% higher versus age-matched men (n=21,229 1 women vs. n=15,918 men). Starting with 60 and up to 85 years of age, the data show a relative 2 decrease in frequency among women (n=7,334 women vs. n=7,171 men). In older women and 3 andropause men (age strata 65 to 80), the statistical susceptibility to viral infection converges 4 (see the closely-matched red and blue pairs of bars in Figure 2 , in the range of 65-85-yrs old).

Near the end of life, defined as 85+ years old, the incidence of SARS-CoV-2 infection is higher 6 in women (n=5,865) than in men (n=5,406). At the opposite end of the age spectrum, note that 7 all pre-adolescents (girls and boys) have similar risks of infection. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 24, 2020. . https://doi.org/10.1101/2020.08.21.20179671 doi: medRxiv preprint approximately +50% higher in men vs. women ( Figure 3 ). For older men vs. women (those 1 >50 years of age), the calculated odds-ratio (OR) was 1.68, 95% CI [1.55, 1.81].

2 Correspondingly, a higher risk of death was associated with men; the hazard ratio (HR) was 3 2.7 [1.42, 5.08] with a lower survival probability for men than women. At a timepoint 200 days 4 after diagnosis of SARS-CoV-2 infection, men were associated with a lower chance of survival 5 than women (p<0.0001). Cumulatively, men were more vulnerable to SARS-CoV-2 infection, with a fatality rate in some 10 strata that is roughly +50% higher than that in women. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 24, 2020. Results for the Female Sub-cohort: A Link between Exogenous Estradiol and Outcomes? 6 In order to assess the potential effects of exogenous female sex hormones in enhancing the 7 survival likelihood for women with SARS-CoV-2 infection, we analyzed a sub-cohort of only 8 women. A logistic regression analysis was performed for the combined outcome variable 9 "death". The outcome was calculated for n=18,892 women, aged 15-49 years, who used oral 10 contraceptives such as estradiol and ethinylestradiol (defined as a 'user' group), or without 11 regular use of oral contraceptives (defined as 'non-user'); we also included n=16,891 peri-and After matching the data of propensity scores for women aged 50+ with COVID-19, there was 16 found to be a benefit for the estradiol hormone-user group vs. the non-user group, as regards 17 an outcome of fatality. The OR calculated via logistic regression analysis for the combined 18 . CC-BY 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 24, 2020. The data for women 15-49 years of age, who were either documented users or non-users of 9 oral contraception (estradiol, ethinylestradiol), were analyzed by logistic regression models.

The effect was smaller than in the peri-and post-menopausal group (aged 50+). The OR 11 calculated with logistic regression analysis for the combined outcome variable "death" was 1.0

[0.41, 2.4] for the non-user group vs. the oral contraception-user group (Table 2) . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 24, 2020. . https://doi.org/10.1101/2020.08.21.20179671 doi: medRxiv preprint 1 estradiol user group and n=1,072 died in the non-user group. Peri-and post-menopausal 2 women, aged 50+, benefitted from estradiol hormone use: the 180-day survival probability for 3 this cohort was 96.7%, compared to 84.9% for the non-user group ( Figure 5 ). This study focuses on the incidence and outcome of COVID-19 infections by considering an 11 age-and sex-disaggregated data analysis. We identified a sex-specific distribution of COVID- 12 19 incidence rates, with the highest frequencies being among premenopausal women in the 13 20-55-year age range. We also found a higher fatality rate of men compared to age-matched 14 women, beginning at 50 years of age. The patterns of incidence rates of women and men with SARS-CoV-2 infection, measured 17 using 5-year age strata, differs from the trends in the number of deaths following the same age is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 24, 2020. . https://doi.org/10.1101/2020.08.21.20179671 doi: medRxiv preprint strata ( Figure 3 ). This gender-based discrepancy might hint at different factors as contributing 1 to the differential risks of infection and COVID-19 fatality among women versus men; note that 2 these other factors may be either intrinsic (e.g., physiological/mechanistic) or extrinsic (e.g., The occurrence of most cases of SARS-CoV-2 infection within the reproductive ages-i.e., 11 before age ~50 (see Fig 2 and the dip towards the right-hand side)-hints at an association 12 with relatively higher estrogen levels. General features of the datasets used in our large 13 international COVID-19 cohort, comprising n=68,466 cases, are consistent with the public data 14 for the incidence of coronavirus infection and the fatality rate for COVID-19 disease in 15 Germany, as presented by the Robert-Koch Institute (RKI) website (Robert-Koch-Institut, 16 2020). In our study the incidence of coronavirus infection in young women is about +15% 17 higher than age-matched men; however, the fatality rate is about +50% higher in men than 18 women. 19 The data in our present study indicate that pre-menopausal women are disproportionately 20 more infected with coronavirus than men in the same age brackets, but they do not become 21 as seriously ill, as evidenced by lower fatality rates; we believe this to be an interesting 22 observation for sex and gender medicine experts. 23 Gender-specific epidemiological differences, with pathophysiological bases, have been 24 published in the recent past, pointing to potential mechanistic roles for the sex hormones. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 24, 2020. . https://doi.org/10.1101/2020.08.21.20179671 doi: medRxiv preprint regulation by androgens, should also be considered other biochemical/physiological factors 1 to which gender-correlated discrepancies might be attributed (Dorak & Karpuzoglu, 2012). Figure 6 schematizes the potential downstream influence of 17β-estradiol on the renin-4 angiotensin-aldosterone system (RAAS), including protective effects for target organs and 5 tissues such as those of the lung, kidney, heart, cardiovascular system, adipose tissue, gut, 6 testes, and the central nervous system. We emphasize that this diagram offers a tentative 7 hypothesis for the mechanistic pathways that could be most salient in SARS-CoV-2 infections In terms of molecular mechanisms, note that 17β-estradiol acts to block the IL-6 cytokine 14 pathway and downregulate the angiotensin II (Ang II)-angiotensin II receptor type 1 (AT1R) 15 signaling pathway. One route by which it does so is by inhibiting the activity of angiotensin- 16 converting enzyme (ACE), as schematized in Figure 6 . Also, as mentioned in the Introduction, 17 the classical ACE-Ang II-AT1R regulatory axis and the ACE2-Ang 1-7-MasR/AT2R signaling is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 24, 2020. Fig 6) . 17β-estradiol attenuates this latter pathway by inhibiting IL-6 activity (Fig 6) . In 9 conclusion, the levels of cell-surface-exposed ACE2 generally will be higher in women is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 24, 2020. . https://doi.org/10.1101/2020.08.21.20179671 doi: medRxiv preprint Figure 6 : A hypothetical mechanistic pathway for the presumably protective role of 17β-1 estradiol in SARS-CoV-2 infection. The membrane-tethered ACE2 protein has an amino-2 terminal catalytic domain (a peptidase) that faces the extracellular space. 24 We assume that premenopausal women have higher basal ACE2 serum levels than age-25 matched men-a scenario that could translate into a higher risk of SARS-CoV-2 infection in 26 women. Higher basal ACE2 levels could be due to the effects of estradiol on RAAS ( Figure 6) 27 and/or the fact that the ACE2 and AT2R genes map to the X chromosome. In genetic terms, 28 this sex-linkage would allow women to be heterozygous and differently assorted compared to is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 24, 2020. . https://doi.org/10.1101/2020.08.21.20179671 doi: medRxiv preprint men, who are hemizygous (Gemmati et al., 2020) . The second X chromosome is not 1 inactivated in approximately 15 % of genes consistently escape from this inactivation and 2 another 15 % of genes vary between individuals or tissues in whether they are subject to, or 3 escape from, inactivation (Balaton, Cotton, & Brown, 2015) . This may account for some of the 4 differences that are seen between men and women (sexual dimorphism) and could be a 5 reason for higher expression levels of ACE2-and ATIIR proteins in women (i.e., a gene dosage 6 effect). Another pertinent mechanistic pathway, potentially triggered or modulated by the types and 9 levels of sex hormones, could be immunological-namely, gender-specific differences in the 10 immune response to SARS-CoV-2 infection. A recent study has linked higher mortality among 11 men to a "cytokine storm", which in turn closely relates to the severity of symptoms such as is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 24, 2020. . https://doi.org/10.1101/2020.08.21.20179671 doi: medRxiv preprint effects, including those related to SARS-CoV-2 infection-the second part of our retrospective 1 data analysis examines the outcome (required ventilation and death) of pre-and post-2 menopausal women with SARS-CoV-2 infection, including as a function of whether or not 3 exogenous estradiol is in use. In performing this analysis, we again employed the large, 4 international COVID-19 cohort developed in this study. To our knowledge, this is the first report 5 that has evaluated the impact of exogenous estradiol sex hormonal use, either for 6 contraceptive purposes or for postmenopausal symptoms, on COVID-19 fatality. Note that other current trials are testing the effect of sex hormones (estrogen and testosterone) 21 on COVID-19 outcomes. A brief, seven-day course of estradiol, delivered via a transdermal 22 patch, could be a safe approach to reduce symptom severity in adult men and in older women, 23 when administered prior to intubation (ClinicalTrials.gov; Identifier: NCT04359329). The time- 24 course for estradiol treatment may need to be evaluated for its positive effects on lung 25 protection, and whether it could be an effective therapeutic approach not only for women but 26 also for men with COVID-19. This type of question cannot be answered solely by the data 27 presented here, and instead addressing this question is a key topic for further research. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 24, 2020. . https://doi.org/10.1101/2020.08.21.20179671 doi: medRxiv preprint 1 Based on the main findings of our present study, we believe there are no concerns for 2 continuing the use of sex hormones that contain estradiol prior to SARS-CoV-2 infection. Even 3 though it can be seen in the data that the risk of infection is higher in pre-menopausal women 4 with higher endogenous estradiol levels, compared to either men of the same age strata or to is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 24, 2020. The data that support the findings of this study are available from TriNetX. While restrictions 8 apply to the availability of these data, which were used under license for the current study and 9 are not publicly available, the data are available from the authors upon reasonable request 10 and with the permission of TriNetX.

Competing interests 12 The authors declare that they have no competing interests 

MS analyzed and interpreted data. 20 FC analyzed and interpreted data. 21 CM was involved in interpretation of the data and helped write the manuscript. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 24, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 24, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 24, 2020. . https://doi.org/10.1101/2020.08.21.20179671 doi: medRxiv preprint

Derivation of consensus inactivation 14 status for X-linked genes from genome-wide studies

17beta-Estradiol, a potential ally to alleviate SARS-CoV-2 18 infection

Sex difference and smoking predisposition in patients with COVID-19

Impact 1 of sex and gender on COVID-19 outcomes in Europe

COVID-4 19 and Individual Genetic Susceptibility/Receptivity: Role of ACE1/ACE2 Genes

Inflammation and Coagulation. Might the Double X-chromosome in

Females Be Protective against SARS-CoV-2 Compared to the Single X-Chromosome 7 in Males?

Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of 10 the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery 11 of ACE2

Clinical Characteristics of Coronavirus Disease 2019 14 in China

SARS-CoV-2 Cell Entry Depends on ACE2

Angiotensin-21 converting enzyme 2 protects from severe acute lung failure

Biological sex impacts COVID-19 outcomes

A crucial role 27 of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung 28 injury

Mortality: Among Hormone-Modulated ACE2 Expression, 31 Risk of Venous Thromboembolism and Hypovitaminosis D

Coronavirus infections and 34 immune responses

The Role of Cytokines 36 including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage 37

Activation Syndrome-Like Disease

COVID-19 disease in Germany presented by the Robert-40 Koch Institute (RKI)

Sex and gender differences in cardiovascular 44 drug therapy

MH analyzed and interpreted data.2 RP conceived the study, matched cohorts, and performed the analysis. 3 SP conceived the study, performed the analysis, and designed Figures. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted August 24, 2020. . https://doi.org/10.1101/2020.08.21.20179671 doi: medRxiv preprint